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Abstract
Background: Our study aims to evaluate the expression of TLR9 in glioma tissues, examine the association
between TLR9 expression, clinicopathological variables, and glioma patient outcome, we further characterized the
direct effects of TLR9 agonist CpG ODN upon the proliferation and invasion of glioma cells in vitro.
Methods: RT-PCR and immunofluorescence were used to determine the expression of TLR9 in glioma cell lines
and clinical glioma samples. Tissue microarry and immunohistochemistry were applied to evaluated TLR9
expression in 292 newly diagnosed glioma and 13 non-neoplastic brain tissues. We further investigated the effect
of CpG ODN on the proliferation and invasion of glioma cells in vitro with MTT assays and matrigel transwell assay
respectively.
Results: RT-PCR showed that TLR9 expressed in all the glioma samples and glioma cell lines we examined. The
tissue array analysis indicated that TLR9 expression is correlated with malignancy of glioma (p < 0.01). Multivariate
Cox regression analysis revealed that TLR9 expression is an independent prognostic factor for PFS of GBM patients
(P = 0.026). TLR9 agonist CpG ODN has no significant effect on glioma proliferation, but matrigel transwell analysis
showed that TLR9 agonist CpG ODN can significantly enhance glioma invasion in vitro.
Conclusions: Our data indicated that TLR9 expression increases according to the histopathological grade of
glioma, and the TLR9 expression level is related to the PFS of GBM patients. In addition, our findings warrant
caution in the directly injection of TLR9 agonist CpG ODN into glioma tissues for the glioma immunotherapy.
Background
Glioma is the most common brain tumor, although with
the combined treatment strategy including surgery,
radiotherapy and chemotherapy, prognosis for high
grade glioma especially glioblastoma multiform (GBM)
altered little over the past 10 years, with a median survi-
val only about 1 year[1], thus new treatment strategy are
urgently needed. Immunotherapy is a promising treat-
ment strategy for gliomas since the activated lymphocyte
can specifically target and destroy tumor cells[2].
Recently, CpG based immunotherapy are intensively
investigated. CpG is synthetic ODN with unmethylated
CG dinucleotides within particular sequence contexts
[3], CpG ODN has been used in clinical trials as a
vaccine adjuvant for immunotherapy of cancer since it
can mimic microbial DNA and activate immune system
through the binding of TLR9. TLR9 belong to TLRs
families which are evolutionarily well conserved trans-
membrane proteins that recognize microbe derived
molecular patterns [4]. TLR9 resides in the endoplasmic
reticulum and its activation results in increased produc-
tion of inflammatory mediators [5,6], Except plasmacy-
toid DC and B cells, TLR9 can also expressed in breast
[7], gastric [8], lung [9] and prostate [10] cancer cells.
Accumulating data indicated that TLR9 agonist CpG
ODN can promote tumor development and metastasis
[7,10-12]. We proposed that TLR9 signal pathway may
also be important in glioma growth and progression.
However its precise role in glioma remains unclear with
studies supporting both glioma promotion and glioma
inhibition results, there is report that local CpG immu-
notherapy can prolong the survival of mouse with
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increase in tumor size following intratumoral injection
of immunostimulatory CpG ODN in a rat glioma
model, this was consistent with our previous finding
that the intratumoral injection of CpG ODN do not
increase the survival time in GL261 glioma animal
model [16], and these results indicated that directly
local injection of CpG may not yield beneficial effects in
glioma patients.
TLR9 expression has been examined in GBMs but not
found to be of prognostic significance [17], however that
investigation is at mRNA level, a protein level study is
thus needed. The aim of this study was to evaluate the
expression of TLR9 in a large series of glioma samples
with tissue array and to examine the association
between TLR9 expression, clinicopathological variables,
and patient outcome. To further characterize the possi-
ble role of TLR9 expression on tumor cells, we examine
the direct effects of CpG ODN upon the proliferation
and invasion of glioma cells in vitro.
Methods
Cells and Cell culture
The human glioma cell lines U87-MG, U251-MG and
rat glioma C6 cell lines were first obtained from ATCC
and maintained in the Central Lab of First Hospital of
China Medical University. Glioma cells were grown in
Dulbecco’s modified essential medium (DMEM, Gibcol,
Gaithersburg, MD, USA) supplemented with 10% FBS
(Hyclone Laboratories, Logan, USA), 100 U/ml penicil-
lin, and 100 μg/ml streptomycin at 37°C with 5% CO2
in humidified air.
CpG ODN and Cell challenge
Nuclease-resistant phosphorothioate-modified oligonu-
cleotides (ODNs) were custom synthesized and purified
by Takara Biotechnology (Dalian, China), The following
sequences were used (the bold letters indicate the CpG
motifs or the GpC motifs of the ODN): ODN 2006,
TCG TCG TTT TGT CGTT T TG T CG TT; ODN
2006 Control, TGC TGC TTT TGT GCTT T TG T G
CTT. The ODNs were dissolved in endotoxin free ster-
ile water, aliquot and stored at -80°C until use.
Immunofluorescence
U87-MG and U251-MG cells were grown on coverslips,
after washing with serum free-DMEM, the cells were
fixed for 10 min with 4% paraformaldehyde in PBS, per-
meabilized with 0.5% Triton X-100 in PBS and blocked
1 h in PBS supplemented with 5% FBS. Cells were incu-
bated overnight at 4°C with TLR9 mAb (Img-305A,
clone 26C593.2, Imgenex, San Diego, USA, 1:400 dilu-
tion), followed by Cy3-labelled anti-mouse secondary
antibody (Sigma, USA, 1:400 dilution) for 2 h. The
nuclei were counterstained with Hoechst (1:1000 dilu-
tions). In the control samples, glioma cells were stained
with secondary antibody and Hoechst, but without anti-
TLR9 primary antibody. Results were observed and
photographed under Leica confocal microscope.
Tissue Samples and Patients
Tumor specimens were obtained from patients admitted
for diagnosis and treatment to First Hospital of China
Medical University and Beijing Tiantan Hospital. The
diagnosis was made according to WHO criteria. The
study was approved by the Ethics Committee of each
institution and was based on the criteria of the Helsinki
convention. Informed consent was obtained from each
patient. Fresh surgical samples from glioma patients and
non-neoplastic brain tissues(temporal lobectomy from
epilepsy surgery) were immediately snap-frozen in liquid
nitrogen upon surgical removal. One part of each sam-
ple was fixed with formalin, embedded with paraffin
wax and kept at RT. The including criteria for the
patients in this study are: 1) Patients do not have other
cancers or diseases such as acute infection, diabetes and
did not receive previous radiotherapy, chemotherapy, or
corticosteroid therapy; 2). Patients had taken routine
contrast-enhanced MRI examination before and after
surgical operation; 3) Patients gave informed consent;
4). Patients who died from non-glioma-related cause
were excluded. The extent of tumor resection was
defined as follows: (0) residual tumor >30% or biopsy;
(1) partial removal with residual tumor ≤ 30%; (2) gross
total resection. Clinicopathological variables were retro-
spectively collected from medical records until July
2009. Progress-free survival (PFS) was defined from the
date of surgery to the first MRI-confirmed recurrence or
death, whichever occurred first.
For the survival analysis, to avoid the bias caused by
different treatment strategy, in addition to the above
screening criteria, patients must have received similar
treatments: surgical resection performed by neurosur-
geons who used similar operational techniques and prin-
ciples. Every patient in the study received the same
radiotherapy regimen. All Patients received chemother-
apy after radiotherapy. The criteria ensured that the
patient group was uniform, which strengthens the analy-
sis. We stopped to collect data at July 2009, the observa-
tion for each patient will end once the patient is dead or
have recurrent. 69 GBM patients fulfill these criteria and
were used for the survival analysis. There are no
patients survived more than 24 months.
RNA Extraction and RT-PCR assay for detection of
Toll-Like Receptor 9
Total RNA was extracted from 3 glioma cell lines and 34
clinical glioma samples using Trizol reagent (Invitrogen,
Wang et al. BMC Cancer 2010, 10:415
http://www.biomedcentral.com/1471-2407/10/415
Page 2 of 11USA), 1 ug RNA was used as template for cDNA Synth-
esis, cDNA was synthesized with First-Strand Synthesis
System for RT-PCR Kit (Catalog No. 11904-018 Invitro-
gen). RT-PCR analyses were performed using the follow-
ing primer sets, human TLR9(sense: 5′-TGTAATA
ACAGTTGCCGTCCAT-3′,a n t i s e n s e :5 ′-CAGCCTT
TCCTTGTCCT CC-3′, product size:344 bp), rat TLR9
(sense: 5′-GGACAGTTCTCTCCACTCGC-3′, antisense:
5′-TTCTTTGAGACGGGAGTGCT-3′, product size: 509
bp), GAPDH(sense: 5′-TCCACCAC CCTGTTGCTGTA-
3′, antisense: 5′-ACCACAGTCCATGCCATCAC-3′, pro-
duct size:450 bp). GAPDH was used as housekeeping
gene control, GADPH consensus primers were shared for
Homo sapiens and Rattus norvegicus. Reactions were car-
ried out in a Gradient Thermal Cycler (Biometra, Goet-
tingen, Germany) for 30 cycles which consisted of 94.0°C
30 s, 55°C 30 s, 72°C 30 s. The reaction took place in a
total volume of 25 ul. Products were analyzed by 1.5%
agarose gel electrophoresis and visualized by Gene finder
staining under ultraviolet. All primers were synthezed by
Takara Biotechnology (Dalian, China). The expression of
TLR9 in U87 and U251 cells were further confirmed by
immunoflurescence analysis, and the expression of TLR9
in glioma tissues were further confirmed by immunohis-
tochemistry method.
Selection of Diffuse Glioma Samples and Construction of
Glioma Tissue Microarray
The formalin-fixed, paraffin embedded archival tissue
blocks were retrieved, and the matching HE-stained slides
were screened for representative tumor regions by a neu-
ropathologist. Glioma samples were then grouped accord-
ing to the diagnostic criteria of the WHO 2000
classification system. The composition of tumors included
in the tissue microarray is listed in Table 1. tissue microar-
ray was constructed with tissue microarrayer (Beecher
Instruments, Silver Springs, MD, USA) as described pre-
viously [18]. The tissue microarray included 292 primary
gliomas representing different histological types and
grades of glioma. Each tumor was sampled in duplicate
from representative areas using a 0.6-mm punch, yielding
composite array blocks comprising a total of 584 tissue
cores. In addition, thirteen non-neoplastic brain tissues
from epilepsy surgical resections were also included. Nor-
mal kidney samples provided by department of surgery
were used as positive control.
Immunochemistry
Paraffin-embedded specimens were cutted into 4 um
sections and baked at 65°C for 30 min. The sections
were deparaffinized with xylenes and rehydrated.
Sections were submerged into EDTA (PH = 8.0) and
autoclaved for antigen retrieval, then treated with 3%
hydrogen peroxide, followed by incubation with 1% FBS.
Anti-TLR9 (Img-305A, clone 26C593.2, Imgenex, San
Diego, USA, 1:100 dilutions) was added and incubated
overnight at 4°C. For negative controls, the primary
antibody was replaced by normal mouse serum. Human
normal kidney samples were used as a positive control.
Horseradish peroxidase (HRP) labeled secondary anti-
body in the MaxVision™ HRP-Polymer antimouse/rabbit
IHC kit (KIT-5930 Maixin Biol, Fu Zhou, China) was
applied and incubated for 30 mins at room temperature,
followed by 5 mins incubation at room temperature
with DAB provided in the kit for color development.
The sections were finally counterstained with haematox-
ylin and mounted with Permount (BIOS, Beijing,
China). Results were visualized and photographed under
a light microscope (Olympus BX-51; Olympus Optical).
The degree of immunostaining of sections was viewed
and scored separately by two independent investigators,
the scores were determined by combining the propor-
tion of positively stained tumor cells and the intensity of
staining. Scores from the two investigators were aver-
aged for further comparative evaluation of the TLR9
expression. The proportion of positively stained tumor
cells was graded as follows: 0 (no positive tumor cells),
1(<10% positive tumor cells), 2 (10-50% positive tumor
cells) and 3 (>50% positive tumor cells). The intensity of
staining were recorded on a scale of 0 (no staining), 1
(weak staining, light yellow), 2(moderate staining, yel-
lowish brown) and 3 (strong staining, brown). The stain-
ing index was calculated as follows: staining index =
staining intensity × proportion of positively stained
Table 1 Composition of tumor types in glioma tissue array
gliomas Number of cases (tissue cores)
Glioblastoma (GBM, WHO Grade IV) 128 (256)
Anaplastic astrocytoma (AA, WHO Grade III) 27 (54)
Diffuse astrocytoma (LGA, WHO Grade II) 33 (66)
Anaplastic oligodendroglioma (AO, WHO Grade III) 16 (32)
Oligodendroglioma (ODG, WHO Grade II) 26 (52)
Anaplastic mixed oligoastrocytoma (AMOA, WHO Grade III) 30 (60)
Oligoastrocytoma (MOA, WHO Grade II) 32 (64)
non neoplastic brain tissue(NB) 13 (26)
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Page 3 of 11tumor cells. The staining index score > 4 was defined as
tumors with high expression, and staining index ≤ 4a s
tumors with low expression of TLR9.
MTT assay
MTT assay was used to assess the effect of CpG ODN
on glioma cells proliferation. Briefly, 1 × 10
4 U87, U251
and C6 cells were seeded into 96-well plates in triplicate
in a volume of 100 ul per well, then incubated at 37°C
for 24 h for cells adherence. CpG ODN(ODN 2006),
ODN 2006 control(10 uM) and same volume of medium
(10 uM) were added, cell growth was measured at 24,
48, 72 hours after the treatment. MTT (Sigma) was dis-
solved in PBS at 5 mg/ml and filtered to be sterilized,
20 ul MTT solution was added at different time points.
Plates were then incubated at 37°C for 4 h, 100 ul
dimethylsulfoxide was added to each well and mixed
thoroughly to dissolve the blue-violet crystals. Cell viabi-
lity data were measured with an ELISA reader (TECAN
SUNRISE, Austria) at 490 nm.
Transwell assay
The invasion assay was done in 24 well cell culture cham-
bers using transwell inserts (Corning life sciences, NY,
Bioscience, San Jose, CA, USA) with 8 um Pore membrane
precotated with matrigel (BD biosciense, San Jose, CA,
USA). U87 cells were plated at the density of 1 × 10
4 per
upper well in 200 ul culture medium (DMEM, 1%FBS), the
lower chamber was filled with 500 μlm e d i u m( D M E M ,
20% FBS). ODN 2006 (10 uM), ODN 2006 control
(10 uM), same volume of the control medium, or Chloro-
quine (10 uM) was added to both upper and lower well.
The cells were allowed to invade for 24 hours, after which,
the noninvading cells with Matrigel matrix were removed
from the upper surface of the membrane by scrubbing
with a cotton-tipped swab. Cells on the lower surface of
the filter were fixed for 30 min in methanol and glacial
acetic acid mixture (3:1), air-dried briefly, and stained with
Giemsa. The number of invaded cells was counted from
five preselected microscopic fields at 200× magnification,
all experiments were performed in triplicate.
Statistical analysis
SPSS statistical software for Windows 13.0 (SPSS, Inc.,
Chicago, Illinois, USA) was used for all statistical analy-
sis. Differences of tumor cell proliferation and invasion
between groups were analyzed by t-test. The Jonc-
kheere-Terpstra test was used to correlate cumulative
TLR9 expression with glioma grading, and the chi-
square test was used for comparisons between groups.
Cox regression was used to correlate TLR9 expression
with PFS while adjusting for clinicopathological vari-
ables. Survival curves were constructed using the
Kaplan-Meier method. The log-rank test was used for
comparison between groups. P ≤ 0.05 was defined as
significance.
Results
TLR9 is expressed in glioma cell lines and tumor samples
The expression of TLR9 mRNAs in glioma cell lines and
tumor tissues were examined using RT-PCR method. As
shown in Fig. 1A, TLR9 is expressed both in human and
rat glioma cell lines, TLR9 expression in glioma tissues
was also shown in Fig. 1A, all the 34 glioma samples
tested in our experiment express TLR9. Housekeeping
gene GAPDH was used as positive control.
Immunofluorescence was used to determine TLR9
protein expressed in human glioma cell lines. A cyto-
plasmic localization of TLR9 in U87 and U251 was con-
firmed by confocal microscopy (Fig. 1B). This finding is
in agreement with previous studies on the distribution
of TLR9 in RAW264.7 cells [19].
Correlation between expression of TLR9 and malignancy
of gliomas
To determine whether the expression level of TLR9 pro-
tein is associated with the histological characteristics of
gliomas, glioma tissue microarray was constructed, sec-
tions were examined by immunohistochemical staining
with an antibody against human TLR9. The anti-TLR9
antibody(Img-305A, clone 26C593.2, Imgenex, San Diego,
USA) was widely used by other researchers. In our
research, during immunohistochemistry staining, primary
antibody control was replaced by normal mouse serum,
which was widely used as negative control in immunoas-
say. Most importantly, we demonstrated that there is no
TLR9 staining in normal brain tissues, which indicated no
false positive staining exist in our study. It was demon-
strated that kidney tubule but not the glomerus have the
expression of TLR9 [8], so we used kidney tubules as posi-
tive control for TLR9 staining in this study. As shown in
Fig. 2A and Table 2, TLR9, mainly as cytoplasmic staining
was found to be expressed in gliomas, no strong immu-
noreactivity (score <4) was detected in non-neoplastic
brain tissues. TLR9 expression was detected in all high
grade glioma cases and was highly expressed(score >4) in
43.78% (88/201) cases (Table 2). We next analyzed the
correlation between the expression of TLR9 protein and
the histological staging of gliomas. As summary in table 2,
expression was significantly higher in high grade gliomas
(grade III and grade IV) compared to low-grade gliomas
(grade II) (P < 0.01), which supported that the TLR9
expression is associated with the progression of glioma.
Association between TLR9 expression and GBM patient
prognosis
To determine the prognostic value of TLR9 protein for
GBM patients, we assessed 69 GBM cases(Recurrent or
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analysis(Table 3), we found that the expression levels of
TLR9 protein were correlated with PFS of GBM patients
(p = 0.013). As shown in Table 3, the multivariate analy-
sis revealed that the expression levels of TLR9 protein
level was a significant prognostic factor in GBM
patients, independent of the conventional clinical vari-
ables (hazard ratio [HR], 3.205; 95% confidence interval
[CI], 1.152-8.920; p = 0.026). In this study, age, gender,
preoperative KPS, and extent of resection were not asso-
ciated with PFS in GBM. We assessed the discriminative
value of expression levels of TLR9 (low expression and
high expression) for survival of patients with GBM
using Kaplan-Meier analysis. We found that the expres-
sion levels of TLR9 could significantly discriminate the
survival of the two GBM subgroups, with a mean PFS
of 9 months (median PFS, 11.108 months; 95% CI,
8.843-13.372) for low TLR9 expression group versus
mean 6 months (median PFS, 6.958 months; 95% CI,
5.634-8.283) for high TLR9 expression group (p =
0.001) (Fig. 2B and Table 3).
CpG-ODN has no effect on glioma proliferation in vitro
MTT assay were performed to investigate the effect of
CpG ODN on the proliferation of glioma cells, glioma
cell lines U87, U251 and C6 were used in this analysis,
our results showed that CpG-ODN (ODN 2006) did not
influence the proliferation rate of the three glioma cell
line tested within 72 hours (Fig. 3), when compared
with non CpG ODN (ODN2006 control) or PBS control.
The ODN 2006 used in this research has been reported
to be efficient activators of cells displaying mRNA
expression of TLR9 [20], and was widely used as a adju-
vant for immunotherapy.
Figure 1 Expression of TLR9 in glioma cell lines and glioma samples. A. mRNA expression of TLR9 (a) Expression of TLR9 in human U87
glioma cell line(lane1) and human U251 glioma cell line(lane2); (b) Expression of TLR9 in rat glioma cell line C6. (c) Expression of TLR9 in 34
clinical glioma samples (lane1-15, Grade IV gliomas; lane16-28, grade III gliomas;lane 29-34, grade II gliomas). GAPDH was used as positive
control. B. Protein expression of TLR9 in human glioma cell lines U87 and U251 with immunofluorescence staining. cytoplasmic localization of
TLR9(red fluorescence, Cy3) in U87 and U251 was confirmed by confocal microscopy, nucleus was stained with Hoechst(Blue fluorescence). (a)
TLR9 staining in U87 cells. (b) Hoechst staining of nucleus in U87 cells. (c) The combined figure of a and b. (d) negative control, staining of U87
cells with secondary antibody and Hoechst, but without primary anti-TLR9 antibody. (e) TLR9 staining in U251 cells. (f) Hoechst staining of
nucleus in U251 cells. (g) The combined figure of e and f. (h) Negative control, staining of U251 cells with secondary antibody and Hoechst, but
without primary anti-TLR9 antibody.
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To study the effects of TLR9 stimulation on the invasion
behavior of glioma cells, we performed invasion assays
using the well characterized TLR9 agonist, ODN2006. As
shown in Fig. 4, the invasion of glioma U87 cells was sig-
nificantly elevated by CpG ODN(ODN2006), compared
with that of glioma cells treated with medium. Similar to
other researchers’ results [11], the non-CpG ODN
(ODN2006 control) can also enhance the invasion of U87
cells. The increased cell numbers seen in the invasion
assays were not due to effect of proliferation, because the
ODN had no effects on cell viability(Fig. 3). In order to
ensure that TLR9 is responsible for the invasion effects
induced by CpG ODN, glioma cells were treated with
CpG ODN in the presence of chloroquine, which is an
inhibitor of endosomal acidification resulting in inhibi-
tion of TLR9 signaling [21]. As shown in Fig. 4, chloro-
quine significantly inhibited CpG ODN induced invasion
in glioma cells, which suggest that TLR9 signaling is
responsible for the enhanced invasion of U87 cells
induced by CpG ODN.
Discussion
Glioma is the most frequent tumor originating from
glial cells in the nervous system, various glioma subtypes
has been divided by grade or by the cell type. Each sub-
type constitutes different genetic mutations [22] and
likely differ in prognosis and response to therapy. We
proposed that there may exist some specific biological
markers related to the clinical behaviors of gliomas,
these markers may also involved in signal pathways that
driving the initiation and development of gliomas.
Recently, researchers showed that virus may be
responsible for the initiation and development of glioma
Figure 2 TLR9 expression in glioma tissues correlated to glioma progression and the prognosis of GBM patients. A.R e p r e s e n t a t i v e
immunohistochemistry staining photos of the glioma tissue arrays. Normal human kidney tissues provided by Department of Surgery were used
as positive control. For negative controls, the primary antibody was replaced by normal mouse serum. Cell nuclei were counterstained with
haematoxylin. B. Kaplan-Meier analysis showing the PFS(progress free survival) of glioblatoma (GBM) patients in low TLR9 expression group (bold
line) and high TLR9 expression group (dotted line). The difference of PFS between the two groups is significant(p = 0.001).
Table 2 TLR9 expression is correlated with glioma
progression
Degree of TLR9 immunoreactivity (%)
Characteristics Low High
Normal brain 13/13(100.00) 0/13(0. 00)
Low Grade
a 80/91 (87.91) 11/91(12.09)
High Grade
b 113/201(56.22) 88/201(43.78)
III
b1 47/73(64.38) 26/73(35.62)
IV
b2 66/128 (51.56) 62/128(48.44)
a, bP=0 . 0 0 0 ;
b1, b2P = 0.078.
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(more than 90%) of GBM tumors, not surrounding nor-
mal brain, are associated with HCMV nucleic acids and
proteins. Thus a virus or inflammation related biomar-
ker may be predictive of glioma progression and devel-
opment. It was demonstrated that HCMV infection
strongly induced TLR9 expression in fibroblast [26].
TLR9 belongs to Toll like receptors, which are a family
of pattern recognition receptors that sense highly con-
served structures from microorganisms [27]. Among the
TLR family, TLR9 recognizes the ODN with CpG motif.
After binding with the ligand, TLR9 signal pathway
leading to subsequent downstream activation of the
NFB, and MAPK signaling pathways [28], which may
responsible for the proinflammatory or progrowth
microenvironment of tumor. Recent studies suggested
that many different tumor cell types, such as colon [29],
prostate [10], breast [7], lung [9] et al express TLR9 and
that TLR9 signaling promotes tumor growth, survival
and immune evasion. Thus we proposed that The TLR9
pathway may also exist and activated in glioma tissues.
There are controversy results for the expression of
TLR9 in glioma cells, Grauer et al [13] showed that
TLR9 are essentially absent at GL261 cells, While Anda-
loussi et al [14] found a strong expression of TLR9 in
GL261 cells with RT-PCR and FCM analysis. This dif-
ference was most likely not caused by the contamination
of genomic DNA at RT-PCR analysis, since Andaloussi
Table 3 Univariate and multivariate analysis of different prognostic parameters for PFS of GBM patients
Variables Value Univariate analysis Multivariate
analysis
p Hazard ratio (95% CI) p
Age* 44.96 ± 12.54 0.682 1.000 (0.982-1.018) 0.983
Gender
Male 39(56.52%) 0.086 0.620 (0.238-1.617) 0.329
Female 30(43.48%)
KPS* 78.00 ± 16.26 0.834 1.014 (0.996-1.033) 0.129
Extent of resection* 1.30 ± 0.77 0.149 1.456 (0.497-4.269) 0.174
TLR9 expression
Low 38(55.07) 0.013 3.205 (1.152-8.920) 0.026
High 31(44.93)
*Mean ± standard deviation
Figure 3 Proliferation of glioma cell lines in response to CpG ODN(ODN 2006). Human U87 glioma cell line, human U251 glioma cell line, and
rat C6 glioma cell line were incubated with CpG ODN(10 uM), CpG ODN Control(10 uM) or same volume of PBS. The analysis was performed in
triplicate and cell growth was measured at 24, 48, 72 hours with an ELISA reader at 490 nm, data was represented as OD value. Bars refer to the
standard error of the mean value. Comparison between groups was made by using student’s t test, P ≤ 0.05 was defined as significant.
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FCM. We preferred Grauer’s data because their result is
consistent with the function of TLR9 signal pathway. As
a receptor for CpG ODN, TLR9 play a key role in tissue
repair and cancer progression, it was demonstrated that
CpGs stimulated the invasion of TLR9+ cancer cells,
but not TLR9- cancer cells [11]. Grauer et al [13]
showed that GL261 is TLR-, which indicated that CpG
ODN may not affect the invasion of GL261 cells, this
was supported by widely accepted results which indi-
cated that CpG ODN induced apoptosis of GL261 in
vitro and cured GL261 glioma animal model in vivo.
Meng et al [17] and Andaloussi et al [14] found that
U87 and U251 express high level of TLR9 mRNA, how-
ever no data about the expression of TLR9 protein in
these two cell lines was reported. To avoid the contro-
versy data like GL261, we investigated the expression of
TLR9 in U87 and U251 cells at both the mRNA level
(RT-PCR) and protein level(immunofluoresence), our
result for the first time showed that TLR9 staining
located intracellularly and could be seen throughout the
cytoplasm in U87 and U251 glioma cells.
The relationship between the expression level of TLR9
and tumor grade of glioma is unknown, to investigate
this, large amount of clinical samples are required.
Meng et al [17]checked the expression of TLR9 in 37
frozen glioma samples, and they found no relationship
between the TLR9 expression and survival, however,
there are several factors may affect their results in their
study: 1. some of the their samples were frozen for a
very long time since 1990. 2. their samples were frozen
under -180°C, the frozen and thawing process may
damage the cells and thus affect the result of immuno-
histochemistry analysis. 3. for the QPCR experiment,
they set a QPCR threshold(0.025) to divide the patients
into low TLR9 group and high TLR9 group, however,
this threshold is not a widely accepted criteria and may
affect their result. 4. Only quantitative RT-PCR data was
used and there is no quantitative protein level data, the
non-neoplastic brain tissues and necrotic tissue, which
have low expression of TLR9, may be included in the
tissues for the extraction of mRNA from the specimen,
and thus may interfere with the result. Because of these
reasons, their results require confirmation with larger
specimen numbers.
We screened the expression of TLR9 in a large collec-
tion of human glioma samples in tissue array with
immunochemistry. With the mutivariant analysis
(Table 3), we found that TLR9 expression is an indepen-
dent prognostic factor to predict patient PFS in GBM
(P <0.05), which indicated that the expression levels of
TLR9 correlate significantly with the clinical outcome of
patients with GBM. Other biological factors such as age,
gender, KPS before surgery, the extent of resection were
not found associated with prognosis. Our research
include same group of patients that was used in one
previous published study [30], which showed that the
resection extent and KPS were not related to the survi-
val, and these data were further supported by other
researcher’s results. Based on the published literature, it
remains unclear whether the extent of surgical resection
correlates with survival [31-33]. Even for KPS, there are
many studies found that it is not associated with survi-
val of GBM patients [34-36]. In addition to this, our
study for the first time demonstrated that TLR9 expres-
sion increased significantly from low grade (grade II)
glioma to high grade (grade III and grade IV) glioma
(Table 2), this result is similar to results obtained by
other researchers with clinical breast specimen [37] and
cervical neoplasia [38]. Present data indicated that TLR9
expression increases according to the histopathological
grade of glioma, and the TLR9 expression level is
related to the PFS of GBM patients.
The potential relationship between TLR9 pathway and
cell proliferation was explored, we demonstrated that
TLR9 activator CpG ODN did not affect the prolifera-
tion of glioma cells in vitro. Merrell et al [11] showed
that treatment of TLR9 expressing breast and brain
Figure 4 Invasion of GBM cell line U87 in response to CpG
ODN(ODN 2006). U87 cells were plated in 24 well cell culture
chambers using transwell inserts precotated with matrigel. ODN
2006 (10 uM), ODN 2006 control (10 uM), same volume of the
control medium, or TLR signaling inhibitor chloroquine (10 uM)
were added and incubated for 24 hours, the number of invaded
cells was stained and counted, all analysis were performed in
triplicate. The invasion ability was represented as numbers of
invaded cells. Bars refer to the standard error of the mean value.
Comparison between groups was made by using student’s t test,
P ≤ 0.05 was defined as significant.
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lates their invasion via MMP 13 activation. In our
research, a different glioma cell line(U87 cells) were
used to ensure whether or not TLR9 is responsible for
the invasive of glioma cells induced by CpG ODN. We
believe that, just like the TLR9 signal pathways in other
cancer cells, the activation of TLR9 may lead to
enhanced invasiveness of U87 glioma cells, this was sup-
ported by our research, we found that the TLR9 agonist
CpG ODN(ODN 2006) can significantly increased the
invasiveness of U87 glioma cells(Fig. 4). Most impor-
tantly, we found that the CpG induced invasion could
be blocked with chloroquine, which is an inhibitor of
TLR9 signaling pathway. All the results suggested that
the expression of TLR9 in glioma cells is functional and
related to the invasiveness of glioma cells. In this
research, we found that non-CpG ODN(ODN2006 con-
trol) can also increase the invasion of glioma cells
through TLR9 signaling pathway, which indicated that
non-CpG ODNs (ODNs from in vivo cells such as dying
tumor cells) may also be able to increase the invasion of
glioma through TLR9 pathway. In addition to this, for
the first time, we showed that chloroquine was able to
inhibit the TLR9 induced invasiveness of glioma cells
(Fig. 4), and thus may be used as an adjuvant for the
GBM therapy, this was confirmed by Briceno et al
[39,40], who showed that chloroquine may improve
mid-term survival when given in addition to conven-
tional therapy for GBM. However, the exact mechanism
for the TLR9 regulation of glioma invasion need further
investigation and is out of the focus of this research.
Our finding has several important implications: First,
they may give novel clues for the investigation of the
mechanism of glioma initiation and development. Sec-
ondly, our findings warrant caution in the directly injec-
tion of TLR9 agonist CpG ODN into glioma tissues for
the glioma immunotherapy., this conclusion may be
contradictory to some researcher’s work [13,41,42].
Although there is contradictory results for the expres-
sion of TLR9 in the GL261 cells between Grauer’s result
[13] and Meng’s result [17], both of them confirmed
that the prolonged survival seen in their study was not
due to the expression of TLR9 expression in glioma
cells, but rather due to increased apoptosis of GL261
cells in vivo and enhanced modulation of the local CNS
immune response. TLR9 expression in non-tumoral
cells or microglia activation may play an important role
in the CpG induced anti-cancer immunotherapy, how-
ever, the inflammatory response observed following
CpG treatment do not always prevent growth of solid
tumor masses, in one CpG treated glioma animal model
[43], intratumoral application of CpG proved ineffective.
In addition to this, Deng et al [44] showed that intracer-
ebral injection of ODN containing CpG motif induce
meningitis in mice and rat. In a phase II trial evaluating
the efficacy of CpG in 34 recurrent GBM patients [45],
patients usually experienced transient neurological wor-
sening or fatigure after intratumoral application of CpG.
In 3 patients, seizure occurred just after administration
of CpG. Our research indicated that locally administered
CpG ODN may increase the invasion of glioma cells.
Based on these data, carefully safety evaluation in animal
model and in large amount of glioma patients should be
performed before CpG can be routinely intratumoral
administered in clinic. For the glioma immunotherapy
strategy with intratumoral injection of CpG ODN, the
most successful animal model is GL261 mouse model
[13,14]. However, we think GL261 was not a perfect
glioma model, since CpG ODN can inhibit GL261 cell
proliferation in a cell type specific manner [13], but for
human cell lines such as U87 and U251, or rat glioma
cell line such as C6, we did not find such effect in this
study(Fig. 3). So, it is difficult to translate the data from
GL261 model into other cell lines or other models. We
did not deny the effectiveness of CpG ODN on tumor
immunotherapy, our previous experiment demonstrated
that the CpG ODN can activate immune system sys-
temically and cure the brain tumor when it was deliv-
ered subcutaneously [16]. We think CpG ODN may
activate TLR9 and promote tumor progression if it was
delivered locally into the tumor within the brain. CpG
ODN may be a magic antitumor weapon, but how to
use it and where to use it is important question, which
may lead to very different result.
We must emphasis that we did not think the TLR9
only express in glioma cells, the infiltrated lymphocyte,
the microglial cells may also express high level of TLR9,
Meng et al [17] indicated that TLR9 was mainly
expressed in infiltrated lymphocyte or microglial cells in
GBM tissues. However, in our study, we found the
glioma cells do express TLR9(Fig. 1). We consider the
glioma tissue as an unseperatabe whole, which was con-
sist of glioma cells, infiltrated lymphocytes and micro-
glial cells et al. The expression of TLR9 in different kind
of cells within the glioma tissue, but not only in glioma
cells, will affect the prognosis of patients with glioma.,
we think the TLR9 expression may reflect inflammatory
microenviroment within glioma tissues.
There may be several reasons for the high expression
of TLR9 in GBM tissues: 1. by stander phenomenon,
the promoter of TLR9 was activated because of other
activated pathways in GBM. 2. The upregulation of
TLR9 could be beneficial to the tumor, promoting survi-
val and the invasiveness of glioma cells, the selective
pressure of the local microenvironment might result in
the ultimate higher expression of TLR9. 3. The presence
of HCMV in gliomas [24] may responsible for the high
TLR9 expression, however, the relationship between the
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At present time, the relationship between inflammation
and tumorigenesis is widely accepted. However, the cel-
lular and molecular mechanism involved in this process
is incompletely understood. Our study indicated that the
TLR9 signaling pathway constitute an important cellular
pathway mediating this interaction in glioma, however,
other independent retrospective and prospective studies
will be necessary before direct clinical application of the
current findings. The exact pathophysiological role of
TLR9 in glioma is not known but it may represent a
useful prognostic biomarker in glioma patients. The
expression of TLR9 in glioma tissues is a major factor,
through them, glioma cells can recognize either micro-
bial pathogens or cellular debris and promote the
expression and secretion of chemokines and cytokines.
We demonstrated the relationship between TLR9
expression and glioma progression. Better understanding
of the function and regulation of the TLR signaling
pathways in glioma may shed new lights on understand-
ing the mechanisms of glioma formation and progres-
sion, as well as provide new targets for more effective
regimens to treat gliomas.
Conclusions
TLR9 recognizes the ODN with CpG motif. After bind-
ing with the ligand, TLR9 signal pathway may induce the
proinflammatory or progrowth microenvironment of
tumor. Our data indicated that TLR9 is expressed in
glioma cell lines and glioma tissues, and the expression
of TLR9 in glioma cells is functional. CpG ODN can sig-
nificantly enhance the invasion of GBM cells, we con-
firmed that TLR9 signaling was responsible for the
enhanced invasion of glioma cells induced by CpG ODN.
Screening a large collection of human glioma samples in
tissue array with immunohistochemistry, we found that
TLR9 expression correlated to the malignancy of gliomas,
and TLR9 expression is an independent prognostic factor
to predict patient PFS in GBM. Our data indicated that
TLR9 may relate to glioma progression and the prognosis
of GBM patients. In addition, our findings warrant cau-
tion in the directly injection of TLR9 agonist CpG ODN
into glioma tissues for the glioma immunotherapy.
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